A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)

NCT01636947 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

494

Enrollment

INDUSTRY

Sponsor class

Conditions

Nausea
Vomiting

Interventions

DRUG: Aprepitant
DRUG: Aprepitant Placebo
DRUG: Ondansetron
DRUG: Dexamethasone
DRUG: Ondansetron Placebo
DRUG: Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).

Sponsor

Merck Sharp & Dohme LLC